Bristol Myers Squibb cited lower Revlimid sales as a driver of its falling revenue in

Patients with a rarer form of acute myeloid leukemia now have a frontline treatment option

Most HIV patients in a Phase III study investigating ViiV Healthcare's long-acting injectable

Illumina must pay a €432 million ($476 million) fine for buying the cancer-testing firm

The end of EQRx has officially arrived. EQRx will be acquired by Revolution Medicines in

Dutch biotech argenx launched a $750 million offering the same day it shared promising data

Certain patients with type 1 diabetes now have an option to use cell therapy thanks

AbbVie largely beat expectations in its second-quarter earnings update, and execs were quick to

Peter Marks, the senior FDA official who oversees the regulation of gene therapies, overrode agency

AstraZeneca’s Alexion subsidiary is snapping up a suite of Pfizer’s preclinical gene therapies

Regeneron said late Tuesday that the FDA rejected its new, 8-mg version of its

Sanofi was the mystery “Party A” that engaged in a bidding war with Biogen for

The FDA approved Regeneron’s pozelimab, the first treatment for a rare, hereditary immune disease

Moderna said that preliminary data in humans on its updated Covid-19 vaccine suggest it

CARsgen will test its Claudin18.2 CAR T-cell candidate, dubbed CT041, in combination with Moderna

Genesis Therapeutics, a startup using artificial intelligence to design small molecule drugs, has raised $200

The FDA put a partial clinical hold on Gilead’s magrolimab for acute myeloid leukemia

Johnson & Johnson’s Janssen plans to close down its vaccine and infectious disease unit in

Pfizer said it expects fewer people will be needed to complete its Phase III trial

On a quest not just to catch up with, but leapfrog, Amgen and Mirati in

AstraZeneca’s rare disease asset Ultomiris was presented with a CRL for neuromyelitis optica spectrum

Two biotech companies, Neumora and RayzeBio, hashed out their IPO plans Monday morning, detailing hopes

Verge Genomics has secured its largest deal yet, linking up with AstraZeneca’s rare disease

Scientists at MIT have revamped mRNA Covid jabs to boost their immune responses, potentially paving

Moderna has inked a deal worth up to $1.8 billion with TCR specialist Immatics that

Madrigal Pharmaceuticals has appointed ex-Sanofi executive Bill Sibold as its new CEO, succeeding Paul

Preliminary mid-stage data from two rival TROP2-targeting ADCs advanced by AstraZeneca/Daiichi Sankyo and

Rocket Pharmaceuticals announced Wednesday that it expects to raise $175 million from a stock sale

The FDA's Cardiovascular and Renal Drugs Advisory Committee on Wednesday voted 9-3 in

Flagship Pioneering’s AI-focused startup Generate:Biomedicines has raised another megaround that will push

Moderna is beefing up its pipeline over the next five years with a plan launch

Lonza CEO Pierre-Alain Ruffieux is set to leave the Swiss contract manufacturer at the

BridgeBio will gain about $250 million via a private investment as the biotech nears an

In its second deal announced Wednesday morning, Roche’s Genentech is signing up with Orionis

Travere Therapeutics’ kidney disease drug narrowly failed its confirmatory study seven months after it won

I2o Therapeutics CEO Kurt Graves set out on Thursday to make a case to a

Taysha Gene Therapies discontinued development of a neurodegenerative therapy after the FDA again insisted on

One of the backbones of cancer medicine is shutting down key cancer-driving pathways to

Novo Nordisk will broaden its cardiometabolic pipeline by pairing up with machine learning and drug

Omega Therapeutics, a company designing genetic medicines that dial the output of genes up or

In its latest Big Pharma deal, Ginkgo Bioworks will work with Pfizer to develop new

As Eli Lilly anticipates an FDA weight loss approval for its in-demand diabetes drug

The FDA approved a Houston drugmaker’s tablet for adults with major depressive disorder last

A massive research collaboration between 13 pharmaceutical companies and the UK Biobank has uncovered a

The FDA on Friday unveiled new details around a rare disease pilot program that seeks

Providence, a massive health system based in the Seattle area with 51 hospitals, is launching

Novartis said that its experimental complement inhibitor iptacopan reduced the buildup of protein in the

All companies with drugs on CMS' list for the first round of Medicare price negotiations

Two years later, Novo Nordisk’s $3.3 billion buyout of Dicerna Pharmaceuticals’ RNAi platform is

Stanford scientists have hatched a new type of drug that can turn a cancer promoter